Pre-Cure

About

Funding history · 1 round · — total

Q&A

What is Pre-Cure's primary focus?

Pre-Cure develops advanced functional ex-vivo predictive platforms in oncology, enabling accurate predictions of treatment response outside the body.

What technologies does Pre-Cure utilize in its platform?

Pre-Cure utilizes advanced microfluidics, 3D cell culture, bio-convergence, and artificial intelligence in its customized tumor-on-a-chip technology.

Who are the founders of Pre-Cure?

The founders of Pre-Cure are Dan Simhon, CEO and Director, and Prof. Ofra Benny, CSO and Director.

What kind of treatments can Pre-Cure's platform predict responses for?

Pre-Cure's platform offers predictions for both first and second-line treatment strategies, including chemotherapy and irradiation, as monotherapy or combination therapy.

What is Pre-Cure's business model regarding collaborations?

Pre-Cure collaborates with pharmaceutical companies to accelerate and de-risk preclinical drug candidates.

Where did the technology behind Pre-Cure originate?

The technology behind Pre-Cure resulted from extensive research conducted at the Nanomedicine & Tumor Microenvironment lab at the Hebrew University of Jerusalem, led by Prof. Ofra Benny.

Team · 13

Dan Simhon

Founder · CEO, Director

Prof. Ofra Benny

Founder · CSO, Director

Dr. Oded Kopper

CTO

Mor Ozeri

Biological Researcher

Alina Ruiz de Villa Maliútina

Scientist

Dr. Rebecca Fima

Research associate

Prof. Aron Popvtzer

Head of Sharett Cancer Institute Hadassah University Hospital (Scientific Board)

Prof. Gideon Bahar

Senior physician at the Department of Otolaryngology at the Beilinson Hospital of the Rabin Medical Center (Scientific Board)

David Hammer

Director (Advisor)

Parul Chansoria

Regulatory Advisor (Advisor)

Clive Kabatznik

Director (Advisor)

Cynthia Ray

VP of Business Development (Advisor)

Dr. Talia Cohen Solal

Director (Advisor)

Sectors & technology